Comparative Survival of Asian and White Metastatic Castration-Resistant Prostate Cancer Men Treated With Docetaxel. Issue 2 (29th January 2020)

• Record Type: Journal Article
• Authors: Halabi, Susan; Dutta, Sandipan; Tangen, Catherine M; Rosenthal, Mark; Petrylak, Daniel P; Thompson, Ian M; Chi, Kim N; De Bono, Johann S; Araujo, John C; Logothetis, Christopher; Eisenberger, Mario A; Quinn, David I; Fizazi, Karim; Morris, Michael J; Higano, Celestia S; Tannock, Ian F; Small, Eric J; Kelly, William Kevin
• Is Part Of: JNCI cancer spectrum. Volume 4:Issue 2(2020)
• Publication Date: 2020-01-29
• DOI: 10.1093/jncics/pkaa003
• Languages: English
• ISSNs: 2515-5091

Abstract

Abstract: There are few data regarding disparities in overall survival (OS) between Asian and white men with metastatic castration-resistant prostate cancer (mCRPC). We compared OS of Asian and white mCRPC men treated in phase III clinical trials with docetaxel and prednisone (DP) or a DP-containing regimen. Individual participant data from 8820 men with mCRPC randomly assigned on nine phase III trials to receive DP or a DP-containing regimen were combined. Men enrolled in these trials had a diagnosis of prostate adenocarcinoma. The median overall survival was 18.8 months (95% confidence interval [CI] = 17.4 to 22.1 months) and 21.2 months (95% CI = 20.8 to 21.7 months) for Asian and white men, respectively. The pooled hazard ratio for death for Asian men compared with white men, adjusted for baseline prognostic factors, was 0.95 (95% CI = 0.84 to 1.09), indicating that Asian men were not at increased risk of death. This large analysis showed that Asian men did not have shorter OS duration than white men treated with docetaxel.